Nuvation Bio Inc. (NUVB)
NYSE: NUVB · Real-Time Price · USD
2.960
-0.020 (-0.67%)
Dec 3, 2024, 11:54 AM EST - Market open
Nuvation Bio Employees
Nuvation Bio had 51 employees as of December 31, 2023. The number of employees decreased by 2 or -3.77% compared to the previous year.
Employees
51
Change (1Y)
-2
Growth (1Y)
-3.77%
Revenue / Employee
$42,392
Profits / Employee
-$10,436,882
Market Cap
996.24M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 51 | -2 | -3.77% |
| Dec 31, 2022 | 53 | -11 | -17.19% |
| Dec 31, 2021 | 64 | 28 | 77.78% |
| Dec 31, 2020 | 36 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Healthcare Services Group | 33,400 |
| AMN Healthcare Services | 3,585 |
| Phibro Animal Health | 1,940 |
| Immatics | 535 |
| Poseida Therapeutics | 330 |
| Zymeworks | 278 |
| Collegium Pharmaceutical | 197 |
| Liquidia | 145 |
NUVB News
- 7 days ago - Nuvation Bio to Present at the 7th Annual Evercore ISI HealthCONx Conference - Business Wire
- 20 days ago - Nuvation Bio to Present at the Jefferies London Healthcare Conference - Business Wire
- 22 days ago - Top 4 Health Care Stocks That May Plunge This Quarter - Benzinga
- 26 days ago - Nuvation Bio Reports Third Quarter 2024 Financial Results and Provides Business Update - Business Wire
- 2 months ago - Nuvation Bio Appoints Industry Veteran Philippe Sauvage as Chief Financial Officer - Business Wire
- 2 months ago - Positive Pooled Data from Nuvation Bio's TRUST-I and TRUST-II Studies Highlight Taletrectinib's Best-in-Class Potential for Patients with Advanced ROS1-positive NSCLC, Supporting Planned New Drug Application Submission in the Fourth Quarter of 2024 - Business Wire
- 3 months ago - Nuvation Bio to Present at the Cantor Global Healthcare Conference - Business Wire
- 4 months ago - Nuvation Bio: Continuing To Justify A Buy Thesis With Catalysts In 2024 - Seeking Alpha